FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry and discloses an isolated antibody which specifically binds a human interleukin-4 receptor α (hlL-4Ra). The antibody includes a VH antibody domain which contains a set of CDR: HCDR1, HCDR2, HCDR3 and a framework region, and a VL antibody domain containing a set of CDR: LCDR1, LCDR2 and LCDR3 and a framework region, wherein the set of CDR has 10 or less substitutions of amino acids selected from the set of CDR, where: HCDR1 is characterised by amino acid sequence SEQ ID NO:193; HCDR2 is characterised by amino acid sequence SEQ ID NO:194; HCDR3 is characterised by amino acid sequence SEQ ID NO:195; LCDR1 is characterised by amino acid sequence SEQ ID NO:198; LCDR2 is characterised by amino acid sequence SEQ ID NO:199; and LCDR3 is characterised by amino acid sequence SEQ ID NO:200, and where the substitutions do not result in loss of the capability to bind hIL-4Ra.
EFFECT: invention broadens the range of antibodies that specifically bind interleukin-4 receptor α.
15 cl, 17 dwg, 7 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODIES TO CANINE INTERLEUKIN-4 ALPHA RECEPTOR | 2016 |
|
RU2736732C2 |
IL-17 ANTAGONIST ANTIBODIES | 2005 |
|
RU2426741C2 |
THERAPEUTIC ANTIBODIES | 2012 |
|
RU2616881C2 |
ANTI c-Met RECEPTOR PROTEIN ANTIBODIES | 2011 |
|
RU2608644C2 |
HUMANISED ANTI-IL-10 ANTIBODIES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | 2010 |
|
RU2587622C2 |
IL-4 AND/OR IL-13 BINDING ANTIBODIES AND USING THEM | 2008 |
|
RU2580049C2 |
HUMAN IL-13 ANTIBODY MOLECULES | 2004 |
|
RU2387667C2 |
METHODS OF TREATING S. AUREUS-ASSOCIATED DISEASES | 2013 |
|
RU2661406C2 |
METHOD OF DESTROYING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES | 2007 |
|
RU2429246C2 |
IL-13 RECEPTOR ALPHA 1 ANTIBODIES AND THEIR APPLICATION | 2006 |
|
RU2413736C2 |
Authors
Dates
2013-08-20—Published
2008-12-19—Filed